vs
INVO Fertility, Inc.(IVF)与阿帕奇(LASE)财务数据对比。点击上方公司名可切换其他公司
INVO Fertility, Inc.的季度营收约是阿帕奇的1.9倍($1.8M vs $919.3K),INVO Fertility, Inc.净利率更高(-150.5% vs -506.4%,领先355.9%),阿帕奇同比增速更快(28.3% vs 22.6%),过去两年INVO Fertility, Inc.的营收复合增速更高(12.8% vs -3.9%)
INVO Fertility是一家专注于辅助生殖医疗解决方案的企业,核心产品为专利INVOcell阴道内培养装置,服务北美、欧洲等地区的生殖诊所与患者,致力于降低生育治疗门槛,为有需求的群体提供可负担的生殖医疗服务。
IPG光子公司是光纤激光器制造商,研发并商业化推广光纤激光器产品,其产品广泛应用于材料加工、医疗、电信等多个领域,目前在美国、德国、俄罗斯和意大利均设有生产基地。
IVF vs LASE — 直观对比
营收规模更大
IVF
是对方的1.9倍
$919.3K
营收增速更快
LASE
高出5.7%
22.6%
净利率更高
IVF
高出355.9%
-506.4%
两年增速更快
IVF
近两年复合增速
-3.9%
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $1.8M | $919.3K |
| 净利润 | $-2.6M | $-4.7M |
| 毛利率 | — | -20.1% |
| 营业利润率 | -93.1% | -350.0% |
| 净利率 | -150.5% | -506.4% |
| 营收同比 | 22.6% | 28.3% |
| 净利润同比 | -62.2% | -186.5% |
| 每股收益(稀释后) | $-0.77 | $-0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
IVF
LASE
| Q3 25 | $1.8M | $919.3K | ||
| Q2 25 | $1.9M | $2.6M | ||
| Q1 25 | $1.6M | $2.3M | ||
| Q4 24 | $1.7M | $1.3M | ||
| Q3 24 | $1.4M | $716.7K | ||
| Q2 24 | $1.8M | $623.4K | ||
| Q1 24 | $1.6M | $743.0K | ||
| Q4 23 | $1.4M | $994.6K |
净利润
IVF
LASE
| Q3 25 | $-2.6M | $-4.7M | ||
| Q2 25 | $-5.3M | $-1.8M | ||
| Q1 25 | $-17.4M | $-1.7M | ||
| Q4 24 | $-3.6M | $586.4K | ||
| Q3 24 | $-1.6M | $-1.6M | ||
| Q2 24 | $-2.2M | $-934.3K | ||
| Q1 24 | $-1.6M | $-545.7K | ||
| Q4 23 | $-2.0M | $-486.6K |
毛利率
IVF
LASE
| Q3 25 | — | -20.1% | ||
| Q2 25 | — | 53.5% | ||
| Q1 25 | 35.2% | 49.8% | ||
| Q4 24 | 41.4% | 13.3% | ||
| Q3 24 | 31.0% | 85.0% | ||
| Q2 24 | 53.1% | 50.6% | ||
| Q1 24 | 45.3% | 51.9% | ||
| Q4 23 | 33.0% | 84.5% |
营业利润率
IVF
LASE
| Q3 25 | -93.1% | -350.0% | ||
| Q2 25 | -160.4% | -37.0% | ||
| Q1 25 | -1042.1% | -68.7% | ||
| Q4 24 | -202.0% | -255.1% | ||
| Q3 24 | -90.7% | -238.0% | ||
| Q2 24 | -100.9% | -149.4% | ||
| Q1 24 | -95.7% | -73.8% | ||
| Q4 23 | -109.2% | -88.4% |
净利率
IVF
LASE
| Q3 25 | -150.5% | -506.4% | ||
| Q2 25 | -283.6% | -68.3% | ||
| Q1 25 | -1060.1% | -73.4% | ||
| Q4 24 | -211.3% | 45.7% | ||
| Q3 24 | -113.8% | -226.8% | ||
| Q2 24 | -122.2% | -149.9% | ||
| Q1 24 | -101.3% | -73.4% | ||
| Q4 23 | -144.4% | -48.9% |
每股收益(稀释后)
IVF
LASE
| Q3 25 | $-0.77 | $-0.27 | ||
| Q2 25 | $-13.30 | $-0.12 | ||
| Q1 25 | $-12.53 | $-0.12 | ||
| Q4 24 | $14.86 | $0.06 | ||
| Q3 24 | $-15.11 | $-0.13 | ||
| Q2 24 | $-22.39 | $-0.09 | ||
| Q1 24 | $-7.55 | $-0.06 | ||
| Q4 23 | $-59.51 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | — | $3.6M |
| 总债务越低越好 | $2.0M | — |
| 股东权益账面价值 | $5.8M | $4.1M |
| 总资产 | $18.8M | $17.5M |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势,按日历期对齐
现金及短期投资
IVF
LASE
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $78.5K | ||
| Q1 25 | — | $179.1K | ||
| Q4 24 | — | $533.9K | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $2.7M | ||
| Q1 24 | — | $5.2M | ||
| Q4 23 | — | $6.2M |
总债务
IVF
LASE
| Q3 25 | $2.0M | — | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $7.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
股东权益
IVF
LASE
| Q3 25 | $5.8M | $4.1M | ||
| Q2 25 | $2.6M | $4.3M | ||
| Q1 25 | $3.3M | $6.8M | ||
| Q4 24 | $12.7M | $10.2M | ||
| Q3 24 | $-23.3K | $9.7M | ||
| Q2 24 | $1.4M | $10.3M | ||
| Q1 24 | $10.2K | $12.4M | ||
| Q4 23 | $892.8K | $13.9M |
总资产
IVF
LASE
| Q3 25 | $18.8M | $17.5M | ||
| Q2 25 | $19.3M | $14.9M | ||
| Q1 25 | $31.7M | $16.0M | ||
| Q4 24 | $46.4M | $17.2M | ||
| Q3 24 | $17.0M | $10.6M | ||
| Q2 24 | $17.8M | $11.1M | ||
| Q1 24 | $17.3M | $13.6M | ||
| Q4 23 | $18.5M | $15.1M |
负债/权益比
IVF
LASE
| Q3 25 | 0.34× | — | ||
| Q2 25 | 1.83× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.59× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-1.8M | $763.1K |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | — |
| 自由现金流率自由现金流/营收 | -101.6% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-7.8M | — |
8季度趋势,按日历期对齐
经营现金流
IVF
LASE
| Q3 25 | $-1.8M | $763.1K | ||
| Q2 25 | $-1.7M | $-1.0M | ||
| Q1 25 | $-3.5M | $-1.2M | ||
| Q4 24 | $-617.4K | $-6.5M | ||
| Q3 24 | $-640.8K | $632.7K | ||
| Q2 24 | $-1.5M | $-2.4M | ||
| Q1 24 | $-260.6K | $-866.3K | ||
| Q4 23 | $-714.9K | $-2.0M |
自由现金流
IVF
LASE
| Q3 25 | $-1.8M | — | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-3.6M | — | ||
| Q4 24 | $-696.3K | — | ||
| Q3 24 | — | $589.6K | ||
| Q2 24 | $-1.5M | $-2.4M | ||
| Q1 24 | $-310.3K | $-1.0M | ||
| Q4 23 | — | — |
自由现金流率
IVF
LASE
| Q3 25 | -101.6% | — | ||
| Q2 25 | -92.6% | — | ||
| Q1 25 | -216.9% | — | ||
| Q4 24 | -40.6% | — | ||
| Q3 24 | — | 82.3% | ||
| Q2 24 | -82.3% | -388.0% | ||
| Q1 24 | -19.7% | -136.9% | ||
| Q4 23 | — | — |
资本支出强度
IVF
LASE
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.9% | — | ||
| Q4 24 | 4.6% | — | ||
| Q3 24 | 0.0% | 6.0% | ||
| Q2 24 | 3.0% | 5.1% | ||
| Q1 24 | 3.2% | 20.3% | ||
| Q4 23 | — | — |
现金转化率
IVF
LASE
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -11.11× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图